De Novo device
Irregular Rhythm Notification Feature (IRNF)
Apple, Inc. · Photoplethysmograph Analysis Software For Over-The-Counter Use (QDB, Class II) · First FDA decision Sep 11, 2018, newest Jul 21, 2023Atrial fibrillation
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
De Novo pathway
Device trials
4
Naming "Irregular Rhythm Notification"
MAUDE reports
0
Brand "Irregular Rhythm Notification", since 2015
PubMed studies
10
Mentioning "Irregular Rhythm Notification"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Irregular Rhythm Notification Feature (IRNF)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K231173 · Decided Jul 21, 2023 · 87 days after receipt
Device type: Photoplethysmograph Analysis Software For Over-The-Counter Use (QDB) · Cardiology
- Irregular Rhythm Notification FeatureNew device typeDe Novo
DEN180042 · Decided Sep 11, 2018 · 33 days after receipt
Device type: Photoplethysmograph Analysis Software For Over-The-Counter Use (QDB) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Irregular Rhythm Notification", any status and sponsor, newest update first.
Emory UniversityAcademic, hospital or other
NCT05795842 · 500 participants (planned) · Start Mar 21, 2023 · Primary completion Dec 2027
Device: wearable wristband model; Standard of care extended ECG monitoring · For: Stroke, Ischemic
Sites: Atlanta, Georgia
- Detection and Quantification of Atrial Fibrillation in High-risk Patients Using a Smartwatch Wearable (Apple Watch)Pivotal-lookingCompleted
Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)Academic, hospital or other
NCT05686330 · 436 participants · Start Nov 16, 2022 · Primary completion Jul 17, 2025
Device: Apple Watch · For: Atrial Fibrillation
Sites: Amsterdam, Netherlands; Haarlem, Netherlands
VitalConnect Inc.Not on our public-company list
NCT04556240 · 0 participants · Start Sep 15, 2020 · Primary completion Oct 30, 2020
Device: VitalConnect Platform · For: Arrhythmias, Cardiac
Sites: Chevy Chase, Maryland
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Irregular Rhythm Notification", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QDB
1 reports: 1 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Irregular Rhythm Notification"[tiab]. The summary above synthesizes these.
- Accuracy of the Apple watch for detection of AF: A multicenter experience.
Wasserlauf J, Vogel K, Whisler C, et al. · J Cardiovasc Electrophysiol · 2023Multicenter Study, Research Support, Non-U.S. Gov't
- Does early detection of atrial fibrillation reduce the risk of thromboembolic events? Rationale and design of the Heartline study.
Gibson CM, Steinhubl S, Lakkireddy D, et al. · Am Heart J · 2023Research Support, Non-U.S. Gov't, Clinical Trial Protocol
- Individualized prediction of atrial fibrillation onset risk based on lifelogs.
Kimura T, Jinzaki M, Miyama H, et al. · Am J Prev Cardiol · 2025
- Heart Watch Study: protocol for a pragmatic randomised controlled trial.
Dhruva SS, Shah ND, Vemulapalli S, et al. · BMJ Open · 2021Clinical Trial Protocol, Research Support, Non-U.S. Gov't
- Accuracy of a Smartwatch to Assess Heart Rate Monitoring and Atrial Fibrillation in Stroke Patients.
Meza C, Juega J, Francisco J, et al. · Sensors (Basel) · 2023
- The Heartline Experience: Achieving Long-Term Participant Engagement in Digital Health Technology Trials.
Nikolovski J, Navar AM, Steinhubl S, et al. · JACC Adv · 2025
- Wearable Devices, Health Care Use, and Psychological Well-Being in Patients With Atrial Fibrillation.
Rosman L, Lampert R, Zhuo S, et al. · J Am Heart Assoc · 2024Research Support, N.I.H., Extramural
- Direct-to-Participant Enrollment in a Virtual Trial: Lessons Learned From the Heartline Study.
Hills MT, Korjian S, Chi G, et al. · JACC Adv · 2026
- Impact of atrial fibrillation burden on quality of life and prediction of health care utilization: Primary results from the DEFINE AFib study.
Piccini JP, Russo AM, Peacock J, et al. · Heart Rhythm · 2026Multicenter Study, Observational Study
- Racial and Ethnic Representation and Study Engagement in a Siteless Digital Clinical Trial Using a Smartwatch: Findings From the Apple Heart Study.
Nguyen KT, Yu J, Hedlin H, et al. · Mayo Clin Proc Digit Health · 2025
Other devices of this type
Also filed under product code QDB.
- Atrial Fibrillation History FeatureApple, Inc. · 510(k) 2022
- Fitbit Irregular Rhythm NotificationsFitbit, Inc. · 510(k) 2022
- IRNF AppApple, Inc. · 510(k) 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.